NTLA - Intellia Therapeutics, Inc.
IEX Last Trade
12.06
-10.470 -86.816%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$22.53
-10.47
-46.47%
Fundamental analysis
18%
Profitability
25%
Dept financing
5%
Liquidity
75%
Performance
0%
Performance
5 Days
-1.07%
1 Month
-18.53%
3 Months
-41.77%
6 Months
-49.79%
1 Year
-61.58%
2 Year
-65.55%
Key data
Stock price
$12.06
DAY RANGE
$12.12 - $22.53
52 WEEK RANGE
$12.21 - $34.87
52 WEEK CHANGE
-$62.04
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: John M. Leonard
Region: US
Website: intelliatx.com
Employees: 600
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: intelliatx.com
Employees: 600
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis. The firm has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells.
Recent news